法瑞西单抗治疗息肉状脉络膜血管病变负荷期疗效观察

doi:10.11958/20260828

天津医药 ›› 2026, Vol. 54 ›› Issue (8): 870-873.doi: 10.11958/20260828

法瑞西单抗治疗息肉状脉络膜血管病变负荷期疗效观察

孟斌(), 崔敏, 刘昕, 郭寅, 吉昂^△()

北京市海淀医院（北京大学第三医院海淀院区）眼科（邮编100029）

收稿日期:2026-03-29 修回日期:2026-05-10 出版日期:2026-08-15 发布日期:2026-08-07
通讯作者: △E-mail：jiang4815@139.com
作者简介:孟斌（1978），男，副主任医师，主要从事眼底病和葡萄膜炎方面研究。E-mail：ykysmb1230@163.com

Efficacy of faricimab for polypoidal choroidal vasculopathy in the loading stage

MENG Bin(), CUI Min, LIU Xin, GUO Yin, JI Ang^△()

Department of Ophthalmology, Beijing Haidian Hospital（Haidian Section of Peking University Third Hospital）, Beijing 100029, China

Received:2026-03-29 Revised:2026-05-10 Published:2026-08-15 Online:2026-08-07
Contact: △E-mail: jiang4815@139.com

孟斌, 崔敏, 刘昕, 郭寅, 吉昂. 法瑞西单抗治疗息肉状脉络膜血管病变负荷期疗效观察[J]. 天津医药, 2026, 54(8): 870-873.

MENG Bin, CUI Min, LIU Xin, GUO Yin, JI Ang. Efficacy of faricimab for polypoidal choroidal vasculopathy in the loading stage[J]. Tianjin Medical Journal, 2026, 54(8): 870-873.

摘要/Abstract

摘要：

目的评估法瑞西单抗治疗息肉状脉络膜血管病变（PCV）的负荷期疗效。方法纳入2024年8月—2025年12月就诊于该院眼科确诊为PCV并应用法瑞西单抗治疗的患者23例（共23眼），平均年龄（74.2±6.5）岁，包括13只初治眼和10只经治眼。所有患者接受每月1次的法瑞西单抗治疗并连续3个月，评估基线与每次治疗后的最佳矫正视力（BCVA）、中心视网膜厚度（CRT）和中心脉络膜厚度（CCT）变化。3次治疗后评估患者息肉状病变（PL）和浆液性色素上皮脱离（PED）消退比例以及出现干燥黄斑（无视网膜内液和视网膜下液）的比例。结果治疗后患者视功能及解剖学均显著改善。经3次治疗，BCVA从基线0.68±0.27依次分别提升至0.50±0.29、0.46±0.29和0.38±0.25（P<0.01），CRT从基线（422.0±110.4）μm依次分别下降至（291.2±49.0）μm、（272.2±44.7）μm和（260.8±44.9）μm（P<0.01），CCT从基线（256.3±131.5）μm依次分别下降至（249.1±131.2）μm、（245.2±127.6）μm和（239.3±127.0）μm（P<0.01）。3次治疗后，PL消退率47.8%（11/23），浆液性PED消退率73.3%（11/15），干燥黄斑比例78.3%（18/23）。本研究中无药物不良事件发生。结论法瑞西单抗负荷期治疗后PCV患者解剖学及视功能均显著改善，在PL消退方面尤为显著。

关键词: 脉络膜疾病, 息肉, 血管疾病, 治疗结果, 法瑞西单抗, 息肉状病灶

Abstract:

Objective To evaluate the efficacy of faricimab for polypoidal choroidal vasculopathy (PCV) in the loading stage. Methods A total of 23 patients (23 eyes) who were diagnosed with PCV in the ophthalmology department of our hospital from August 2024 to December 2025 and treated with faricimab were included in this study. The average age was (74.2±6.5) years, including 13 newly treated eyes and 10 treated eyes. All patients underwent faricimab therapy once a month for 3 consecutive months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT) and central choroidal thickness (CCT) were evaluated at baseline and after each therapy. Subsequent to the completion of the loading stage, the regression rates of polypoidal lesions (PL) and serous pigment epithelial detachment (PED), along with the proportion of patients with dry macula, were assessed. Results After the treatment, both the visual function and anatomic outcome of patients were improved significantly. The BCVA increased from the baseline of 0.68±0.27 to 0.50±0.29, 0.46±0.29 and 0.38±0.25 after three injections respectively (P<0.01), and the improvement persisted throughout the loading stage. CRT decreased from the baseline of (422.0±110.4) μm to (291.2±49.0) μm, (272.2±44.7) μm and (260.8±44.9) μm (P<0.01) ，and CCT decreased from (256.3±131.5) μm at baseline to (249.1±131.2) μm, (245.2±127.6) μm and (239.3±127.0) μm after three injections, respectively (P<0.01). After the loading stage, the regression rate of PL was 47.8% (11/23), the regression rate of serous PED was 73.3% (11/15) and the proportion of dry macula was 78.3% (18/23). There were no adverse drug events in this study. Conclusion After faricimab loading phase treatment, the anatomical and vision functions of PCV patients improve significantly, especially in the regression of PL.

Key words: choroid diseases, polyps, vascular diseases, treatment outcome, faricimab, polypoidal lesion

中图分类号:

R774.1

图/表 1

参考文献 23

[1]	Yang Z, Zhang W, Gu X, et al. Polypoidal choroidal vasculopathy: In-depth insights and promising future directions[J]. Prog Retin Eye Res, 2026, 110:101414. doi:10.1016/j.preteyeres.2025.101414.
[2]	Cheung C, Lai T, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy:definition,pathogenesis,diagnosis,and management[J]. Ophthalmology, 2018, 125(5):708-724. doi:10.1016/j.ophtha.2017.11.019.
[3]	Koh A, Lee W K, Chen L J, et al. EVEREST study:efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy[J]. Retina, 2012, 32(8):1453-1464. doi:10.1097/IAE.0b013e31824f91e8.
[4]	Koh A H, Expert PCV Panel, Chen L J, et al. Polypoidal choroidal vasculopathy:evidence-based guidelines for clinical diagnosis and treatment[J]. Retina, 2013, 33(4):686-716. doi:10.1097/IAE.0b013e3182852446.
[5]	Cho H J, Kim K M, Kim H S, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2016, 165:1-6. doi:10.1016/j.ajo.2016.02.019.
[6]	Wong T Y, Ogura Y, Lee W K, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy:two-year results of the aflibercept in polypoidal choroidal vasculopathy study[J]. Am J Ophthalmol, 2019, 204:80-89. doi:10.1016/j.ajo.2019.02.027.
[7]	Lee W K, Wong T Y, Chen S J, et al. Aflibercept 8 mg in polypoidal choroidal vasculopathy:post hoc analysis of the PULSAR randomized clinical trial[J]. JAMA Ophthalmol, 2026, 144(2):129-137. doi:10.1001/jamaophthalmol.2025.5098.
[8]	Regula J T, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases[J]. EMBO Mol Med, 2016, 8(11):1265-1288. doi:10.15252/emmm.201505889.
[9]	Sharma A, Kumar N, Kuppermann B D, et al. Faricimab: expanding horizon beyond VEGF[J]. Eye(Lond), 2020, 34(5):802-804. doi:10.1038/s41433-019-0670-1.
[10]	Lee J, Cheung G, Chenet S J, et al. Faricimab for polypoidal choroidal vasculopathy:week 16 results from the phase 3b/4 SALWEEN trial[J]. Invest Ophthalmol Vis Sci, 2025, 66(8):1859.
[11]	Ruamviboonsuk P, Ng D, Chaikitmongkol V, et al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy(PCV)from the Asia-Pacific Vitreo-retina Society (APVRS)[J]. Asia Pac J Ophthalmol (Phila), 2025, 14(1):100144. doi:10.1016/j.apjo.2025.100144.
[12]	Teo K, Gillies M, Fraser-Bell S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy:a subtype of neovascular age-related macular degeneration[J]. Int J Mol Sci, 2018, 19(9):2611. doi:10.3390/ijms19092611.
[13]	Wong C W, Wong T Y, Cheung C M. Polypoidal choroidal vasculopathy in Asians[J]. J Clin Med, 2015, 4(5):782-821. doi:10.3390/jcm4050782.
[14]	Joussen A M, Ricci F, Paris L P, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases:a review of preclinical data[J]. Eye(Lond), 2021, 35(5):1305-1316. doi:10.1038/s41433-020-01377-x.
[15]	Heier J S, Khanani A M, Quezada Ruiz C, et al. Efficacy, durability,and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE):two randomised,double-masked,phase 3,non-inferiority trials[J]. Lancet, 2022, 399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1.
[16]	Otani A, Takagi H, Oh H, et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes[J]. Invest Ophthalmol Vis Sci, 1999, 40(9):1912-1920.
[17]	Ma L, Brelen M E, Tsujikawa M, et al. Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations[J]. Invest Ophthalmol Vis Sci, 2017, 58(2):1076-1083. doi:10.1167/iovs.16-20575.
[18]	Zhang C, Zhang W, Wang T, et al. Polypoidal choroidal vasculopathy:from clinicopathological and molecular perspectives[J]. Ophthalmic Res, 2025, 68(1):521-530. doi:10.1159/000548709.
[19]	Cho J, Han H Y, Park S, et al. One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy:a comparative study[J]. Eye(Lond), 2026, 39(16):2893-2898. doi:10.1038/s41433-025-03980-2.
[20]	Mukai R, Kataoka K, Tanaka K, et al. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan[J]. Sci Rep, 2024, 14(1):11681. doi:10.1038/s41598-024-62559-1.
[21]	Tanaka A, Hata M, Tsuchikawa M, et al. Short-term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration[J]. Clin Ophthalmol, 2024, 18:507-516. doi:10.2147/OPTH.S448507.
[22]	Arnold-Vangsted A, Schou M G, Balaratnasingam C, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy:A systematic review and meta-analysis[J]. Acta Ophthalmol, 2025, 103(3):247-256. doi:10.1111/aos.16797.
[23]	Kim H M, Woo S J. Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs[J]. Curr Ther Res Clin Exp, 2024, 100:100742. doi:10.1016/j.curtheres.2024.100742.

时间点	BCVA（n=23）	CRT/μm（n=23）	CCT/μm（n=20）
治疗前	0.68±0.27	422.0±110.4	256.3±131.5
1针后	0.50±0.29^a	291.2±49.0^a	249.1±131.2^a
2针后	0.46±0.29^a	272.2±44.7^a	245.2±127.6^a
3针后	0.38±0.25^a	260.8±44.9^a	239.3±127.0^a
F	26.180^＊＊	27.591^＊＊	677.700^＊＊

时间点	BCVA（n=23）	CRT/μm（n=23）	CCT/μm（n=20）
治疗前	0.68±0.27	422.0±110.4	256.3±131.5
1针后	0.50±0.29^a	291.2±49.0^a	249.1±131.2^a
2针后	0.46±0.29^a	272.2±44.7^a	245.2±127.6^a
3针后	0.38±0.25^a	260.8±44.9^a	239.3±127.0^a
F	26.180^＊＊	27.591^＊＊	677.700^＊＊

法瑞西单抗治疗息肉状脉络膜血管病变负荷期疗效观察

Efficacy of faricimab for polypoidal choroidal vasculopathy in the loading stage

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘丽, 胡晓甜, 钱雪娇, 蒋萍. 天津市咳嗽患者诊治现状的流行病学调查[J]. 天津医药, 2026, 54(6): 653-657.
[2]	任宝龙, 焦爱菊, 朱若兰, 赵玮婧. 脂蛋白相关磷脂酶A2联合MRI总负荷评分对脑小血管病患者认知障碍的预测价值[J]. 天津医药, 2026, 54(3): 245-248.
[3]	李斌, 谭振刚, 张华清. 基于息肉特征和血清学指标构建结直肠息肉复发风险预测模型及效能分析[J]. 天津医药, 2026, 54(3): 249-253.
[4]	焦爱菊, 朱若兰, 张春花, 李文瑞, 孙霞, 赵玮婧, 任宝龙. 血清Lp-PLA2、Hcy联合WMH对脑小血管病患者认知障碍的预测价值[J]. 天津医药, 2025, 53(8): 846-849.
[5]	李婉婷, 刘弘扬, 桑婧, 阮育凤, 徐丽, 李冬梅. 老年下肢骨折患者术后发生急性心脑血管意外的影响因素分析[J]. 天津医药, 2025, 53(6): 648-653.
[6]	邓子昊, 黄欣扬, 钟坤江, 赵博. 纳米材料在动脉粥样硬化性心血管疾病中的应用进展[J]. 天津医药, 2025, 53(5): 556-560.
[7]	董文荣, 冯全跃, 秦隆朝, 田立俊, 李倩倩. 疏风通窍汤联合甲泼尼龙片用于慢性鼻窦炎伴鼻息肉患者术后疗效观察[J]. 天津医药, 2025, 53(3): 312-316.
[8]	金佳纯, 陆彩霞, 吴燕君. 中性粒细胞胞外诱捕网对动脉粥样硬化性心血管病的作用机制及其研究进展[J]. 天津医药, 2025, 53(10): 1104-1109.
[9]	马良, 胡立影, 石羽, 龙刚. 光学相干断层扫描血管成像技术在慢性肾脏病临床评估中的应用进展[J]. 天津医药, 2024, 52(8): 882-887.
[10]	吴春叶, 邢钧, 龚宝琪. 贝利尤单抗治疗初发系统性红斑狼疮的短期疗效观察[J]. 天津医药, 2023, 51(7): 771-775.
[11]	张丽君, 李翔威, 谭晓慧. 单侧湿性年龄相关性黄斑变性患者患眼黄斑区GCIPL厚度变化及其与血清IL-8水平的关系[J]. 天津医药, 2023, 51(2): 166-170.
[12]	黄芃菲, 卢成志. 小剂量沙库巴曲缬沙坦用于治疗心力衰竭合并慢性肾脏病1~3期患者的研究[J]. 天津医药, 2022, 50(9): 993-997.
[13]	闻竹, 张贤生. “五步法”低功率直出式绿激光前列腺剜除术治疗大体积前列腺增生的疗效及体会[J]. 天津医药, 2022, 50(7): 743-747.
[14]	王芳, 薛娟娟, 夏晓爽, 尚淑玲, 张福青, 李新. 唐山地区气象因素与急性缺血性卒中患者转归的关系[J]. 天津医药, 2022, 50(3): 305-309.
[15]	韩鹏, 马静, 张楠 , 肖健勇 , 王静娴 , 王缘 , 许仕博, 高静 , 刘寅 . 天津市35岁以上居民对急性心肌梗死危险因素的知晓现状及影响因素 #br#[J]. 天津医药, 2021, 49(6): 651-655.